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Cardiovascular outcome trials in patients with type 2 diabetes (T2DM) at high risk have 
led to remarkable advances in our understanding of the efficacy of glucagon-like 
peptide-1 receptor agonists (GLP-1RA) and sodium glucose cotransporter 2 inhibitors 
(SGLT2i) to reduce cardiorenal events. The American Diabetes Association (ADA), the 
European Association for the Study of Diabetes (EASD), and the European Society of 
Cardiology have recently published recommendations for management of such patients. 
Many health care workers have tended to focus on the differences between the 
endocrinologists’ consensus and the cardiologists’ guidelines while recent reports show 
that only a minority of people with T2DM with preexisting CV disease or heart failure 
receive the treatments advocated by both. A subset of members of both writing groups 
were convened to emphasise where  commonalities exist and to propose an integrated 
paradigm that encompasses the views incorporated in the ESC and ADA/EASD  




Type 2 diabetes mellitus (T2DM) is a complex metabolic disease characterized by the 
presence of hyperglycaemia and leading to the development of micro- and 
macrovascular complications. Overall there is a 2 to 3-fold risk of cardiovascular (CV) 
disease in diabetes which is further magnifiedin the presence of chronic renal 
impairment {Mulnier, 2008 #10060;Bell, 2015 #10061}. In addition to atherosclerotic 
cardiovascular disease (ASCVD), patients with diabetes exhibit an increased risk for 
heart failure, which is associated with further increases in morbidity and mortality 
{McAllister, 2018 #9968}. Glycemic control has been shown to effectively reduce the 
incidence and worsening of microvascular complications such as retinopathy, but has - 
at best - moderate effects on the development of macrovascular complications or heart 
failure {, 1998 #9449;Patel, 2008 #3887} which have remained stubbornly resistant to 
therapeutic innovations {Udell, 2015 #10065}.  
However, over the last decade, several large cardiovascular outcome trials (CVOTs) 
have provided data on the efficacy of glucagon-like peptide-1 receptor agonists (GLP-
1RA) and sodium glucose cotransporter 2 inhibitors (SGLT2i) to reduce cardiorenal 
events in people living with T2DM at high CV risk. The American Diabetes Association 
(ADA), the European Association for the Study of Diabetes (EASD), and the European 
Society of Cardiology (ESC) have recently published strong recommendations for 
prescribing these agents in such patients {Davies, 2018 #10016;Buse, 2020 
#10054;Cosentino, 2020 #10062}. Much has been made of the differences in 
recommendations which largely center on how “high risk” is defined and the role of 
metformin as first line therapy and we have concerns that this focus has contributed  to 
clinical inertia to the detriment of patient care. Over the last 5 years there has been a 
growth in clinical evidence for the beneficial CV effects of SGLT2i and GLP-1RA in 
people living with T2DM, and it is of major concern that the number of patients receiving 
these life-saving drugs remains so low {Dennis, 2019 #10063}. A subset of the writing 
group members was convened to find common ground and explore opportunities to 
integrate our efforts. In this expert consensus paper developed after round table 
discussions between  members of the two writing groups we propose an integrated 
paradigm that encompasses the views incorporated in the ESC, ADA and EASD in their 
different approaches to management. We launch a message of ‘awakening,’ 
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encouraging the medical community to apply the evidence originating from large studies 
and taken up in the guidelines/consensus to their clinical practice. 
 
Evidence for SGLT2-inhibitors 
The effect of SGLT2-inhibitors on CV endpoints has been examined in five placebo-
controlled CVOTs in patients with T2DM, providing consistent, strong evidence for the 
ramelioration of both, cardiovascular and renal complications. In the EMPA-REG 
OUTCOME trial Empagliflozin {Zinman, 2015 #9038} and in the CANVAS program 
Canagliflozin {Neal, 2017 #9572} significantly reduced 3-point MACE in a population of 
patients with elevated CV risk (Table 1). In addition, Canagliflozin significantly reduced 
3-point-MACE in a diabetes population with chronic kidney disease (CKD; CREDENCE 
trial) {Perkovic, 2019 #9979}. DECLARE TIMI-58, a trial assessing CV effects of 
Dapagliflozin vs. placebo in patients with diabetes did not find a significant reduction of 
3-point MACE, possibly due to the lower risk cohort recruited with about 60% of 
participants without prevalent CV disease, but multiple risk factors {Wiviott, 2018 
#9939}. The VERTIS CV trial with Ertugliflozin also did not show a reduction in MACE, 
despite the fact that people with already existing CV events were studied (ADA 
Presentation). Convincingly, in all of these trials the SGLT2 inhibitors investigated 
showed a significant reduction of the combined endpoint of heart failure hospitalization 
or CV death. This beneficial effect of SGLT2-inhibitors on heart failure-related events 
has been confirmed by recent data from the DAPA-HF trial as well as the EMPEROR-
reduced trial examining the effect of SGLT2 inhibitors in patients with heart failure with 
reduced ejection fraction (HFrEF) with or without diabetes. In both studies, dapagliflozin 
in DAPA-HF, or empagliflozin in EMPEROR-reduced led to a reduction in the combined 
endpoint of HF worsening or CV death compared to placebo independent of the 
presence of diabetes {McMurray, 2019 #10001;Packer, 2020 #140}.  
Despite using different definitions of renal endpoints, all SGLT2-inhibitor studies also 
showed protection against progression of diabetic kidney disease. In the CVOT studies, 
these findings were secondary endpoints, but the CREDENCE study demonstrated a 
highly significant 30% reduction in the combined cardio-renal endpoint of composite of 
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ESKD, doubling of serum creatinine, death from kidney causes or CV death in people 
with T2DM and CKD {Perkovic, 2019 #9979}. In addition, most recently, DAPA-CKD, a 
dedicated trial in CKD patients with or without diabetes , demonstrated a significant 
reduction of the composite endpoint of sustained ≥50% eGFR decline, ESKD, renal or 
CV death, a reduced risk of CV death or hospitalisation for heart failure, as well as a 
reduction of all-cause mortality independent of diabetes status. 
Evidence for GLP-1 receptor agonists 
GLP-1 receptor agonists are arguably the most effective glucose lowering medications 
and weight loss agents indicated for the treatment of T2DM. In a series of seven 
published CVOT’s, four agents to date have demonstrated statistically significant 
reductions in the hazard ratio for the first occurrence of the 3-point MACE composite of 
non-fatal myocardial infarction, non-fatal stroke or CV death (liraglutide {Marso, 2016 
#9446}, subcutaneous semaglutide {Marso, 2016 #9447}, albiglutide {Hernandez, 2018 
#9925}, and dulaglutide {Gerstein, 2019 #9997})(Table 2). Two agents have shown 
numerical reductions in 3-point MACE (exenatide once weekly {Holman, 2017 #9600} 
and oral semaglutide {Husain, 2019 #9996}) and one was effectively neutral 
(lixisenatide {Pfeffer, 2015 #9030}) without evidence of cardiovascular harms or 
benefits. Meta-analyses of the trial results (overall population 56,004 participants), 
demonstrate a 12% reduction in 3-point MACE, 12% reduction in CV death, 11% 
reduction in all-cause mortality, 9% reduction in fatal/non-fatal MI, 16% reduction in 
fatal/non-fatal stroke, 9% reduction in heart failure hospitalization, and 17% reduction 
for a broad kidney composite outcome mainly driven by effects on albuminuria. 
{Kristensen, 2019 #10055;Marsico, 2020 #10056}  
 
ADA / EASD recommendation and ESC guidelines 
First, it is important to understand the context in which both documents were written. 
The ADA/EASD ‘consensus’ is based on a structured review of published evidence of 
pharmacological and non-pharmacological interventions in T2DM over a defined time 
period (Jan 2014 –Feb 2018) but without formal grading of the evidence, aimed at 
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HCPs in Europe and the US. The ESC document is a ‘guideline’ which weighed and 
graded evidence according to ESC criteria leading to 138 recommendations in 14 areas 
of practice and is targeted at practitioners in Europe.  
The ADA/EASD recommended in 2018 {Davies, 2018 #10016} that, in the setting of 
T2DM, established CVD was a compelling indication for treatment with a GLP-1 
receptor agonist or an SGLT2 inhibitor. In the 2019 update {Buse, 2020 #10054}, the 
ADA/EASD further suggested the following (direct quotation): 
• In appropriate high-risk individuals with established T2DM, the decision to treat 
with a GLP-1 receptor agonist or SGLT2 inhibitor to reduce MACE, hHF, CV 
death, or CKD progression should be considered independently of baseline 
HbA1c or individualized HbA1c target.  
• Providers should engage in shared decision making around initial combination 
therapy in new-onset cases of type 2 diabetes. 
• For patients with T2DM and established atherosclerotic CV disease (such as 
those with prior myocardial infarction, ischemic stroke, unstable angina with ECG 
changes, myocardial ischemia on imaging or stress test, or revascularization of 
coronary, carotid, or peripheral arteries) where MACE is the gravest threat, the 
level of evidence for MACE benefit is greatest for GLP-1 receptor agonists. 
• To reduce risk of MACE, GLP-1 receptor agonists can also be considered in 
patients with T2DM without established CVD with indicators of high risk, 
specifically, patients aged 55 years or older with coronary, carotid, or lower 
extremity artery stenosis >50%, left ventricular hypertrophy, eGFR <60 mL min–1 
[1.73 m]–2, or albuminuria. 
• For patients with or without established atherosclerotic CVD, but with HFrEF (EF 
<45%) or CKD (eGFR 30 to ≤60 mL min–1 [1.73 m]–2 or UACR >30 mg/g, 
particularly UACR >300 mg/g), the level of evidence for benefit is greatest for 
SGLT2 inhibitors. 
• SGLT2 inhibitors are recommended in patients with T2DM and HF, particularly 
those with HFrEF, to reduce hHF, MACE, and CV death. 
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• SGLT2 inhibitors are recommended to prevent the progression of CKD, hHF, 
MACE, and CV death in patients with T2DM with CKD. 
• Patients with foot ulcers or at high risk for amputation should only be treated with 
SGLT2 inhibitors after careful shared decision making around risks and benefits 
with comprehensive education on foot care and amputation prevention. 
The 2019 ESC guidelines on diabetes prediabetes and CVD published {Cosentino, 
2020 #10062} recommend that patients with diabetes should be classified according to 
three accepted levels of cardiovascular risk and treated accordingly independent of 
baseline HbA1c levels. The guidelines suggest the following: 
• Patients at very high risk include those with DM and established CVD, or other 
target organ damage (proteinuria, renal impairment defined as eGFR <30 
mL/min/1.73 m2, left ventricular hypertrophy, or retinopathy), or three or more 
major risk factors, or early onset T1DM of long duration (>20 years). High risk 
patients are defined as those with DM duration ≥10 years without target organ 
damage plus any other additional risk factor, and patients at moderate risk are 
young patients (T1DM <35 years; T2DM <50 years) with DM duration <10 years, 
without other risk factors. (Risk factors include: age ≥50, hypertension, 
dyslipidemia, smoking, obesity). 
• In patients at moderate risk metformin be should be considered as first line 
therapy (Class IIa C recommendation). 
• Patients with atherosclerotic cardiovascular disease (ASCVD) as well as those at 
high or very high risk should be treated with an SGLT2 inhibitor or a GLP-1 RA 
(Class IA recommendation). If HbA1c values are not at target in these patients, 
metformin should be added. Further intensification of glucose control should be 
achieved with additional glucose-lowering drugs to reduce microvascular events.  
In the future, studies need to show whether these drugs will be standard for the 
prophylaxis of CVD and / or CKD in uncomplicated T2DM rather than for therapeutic 
purposes only. 
Differences between the Consensus and Guidelines  
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The original ADA/EASD consensus was published in Dec 2018 prior to the full 
publication of a number of the larger CVOTs, including REWIND, DECLARE and 
CREDENCE (6-8). These trials contributed evidence particularly in those with multiple 
CV risk factors, primary renal outcome data and included data on those with HbA1c’s 
below or at target range. The ESC guideline published in Sept 2019 was able to 
consider this evidence. The ADA/EASD consensus was subject to a brief update in Dec 
2019 to reflect these additional data. 
The definition and consideration of ‘at risk’ groups differs.  The ADA/EASD consensus 
identifies specific ‘high risk’ groups based on the inclusion criteria articulated in the 
CVOTs whereas the ESC guideline uses its own definition of cardiovascular risk 
categories modified from the 2016 guidelines and includes people with type 1 diabetes. 
The ESC definition of ‘high’ CV risk is based on duration of diabetes plus additional risk 
factor (age, hypertension, dyslipidaemia, smoking, obesity) and would mean the vast 
majority of people with T2DM would be defined as ‘high’ CV risk {Caparrotta, 2020 
#10064} however it is difficult to judge how closely this group reflects those recruited to 
CVOTs such as DECLARE and REWIND.   
The positioning of the use of glucose lowering therapies in CV protection differs. The 
ADA/EASD consensus gives preference to the use of GLP-1 RA with regards to 
reduction in major adverse cardiovascular event (MACE) in those with established 
atherosclerotic cardiovascular disease (ASCVD) as well as those with ‘high risk 
indicators’, however the SGLT2-i are preferred in those with CKD and heart failure (HF). 
The ESC guideline suggests the use of either GLP1-RA or SGLT2i in patients with 
ASCVD or high or very high CV risk but does not differentiate between use of the 
classes in specific sub-groups (1). 
The area of difference which has attracted most attention is the positioning of 
metformin. In many of these CVOTs patients were on metformin baseline therapy, but 
there is no evidence to suggest that the presence of metformin might have influenced 
the results {Inzucchi, 2020 #141}. The ADA/EASD consensus retains metformin as 
‘foundational’ treatment but explicitly questions whether this is a ‘quirk of history’ rather 
than truly evidence-based and highlights that GLP-RA and/or SGLT2i should be added 
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early regardless of HbA1c.  In contrast, the ESC guidelines remove the requirement to 
start with metformin as first line in those drug naïve with ASCVD or at high or very high 
CV risk, preferring initial therapy with either a GLP-1RA or SGLT2i.  
Similarities between the Consensus and Guidelines  
The main common point between the two documents is that both expert groups put the 
patient at the center of the care pathway and derive their guidance on therapies for 
diabetes from evidence provided by major clinical trials in people with T2DM, with the 
ADA/EASD consensus also bringing in real world evidence. Both documents attempt to 
integrate care to manage the high levels of morbidity and mortality associated with 
T2DM and emphasize the importance of a multifactorial approach to T2DM, including 
glucose lowering therapy, but also blood pressure control, statins and in very high risk 
patients antiplatelet therapy. The importance of diet and lifestyle is emphasized in both 
documents. Of importance in both documents is that choices of agents in the treatment 
of people with diabetes needs to build on evidence that moves beyond HbA1c. Both 
documents recognise the strong evidence for agents from the GLP1-RA and SGLT2i 
class and put these agents high up in the decision tree. Both documents clearly state 
that the concept of individualised care is central to the management of diabetes and 
therapeutic decisions depend on many factors including patient characteristics, co-
morbidities, patient preferences and priorities. 
Both agree that metformin should be first line therapy in newly diagnosed T2DM, 
however in the consensus it is recommended this is applied to all newly diagnosed 
T2DM, whilst the ESC guideline indicates that in the presence of CVD and in those with 
high / very high risk, SGLT-2i or GLP-1 should be first line. This difference is not as 
great as it sounds, as the ADA/EASD insists that patients at high risk for cardiorenal 
disease should be treated with SGLT2i or GLP-1RA independent of HbA1c. In addition, 
most patients rapidly progress to requiring combination therapy and  the addition of 
metformin will probably be required soon after diagnosis. 
 
A call to action – clinical messages 
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1) It is obvious from both the clinical trial data and market data, that there is an 
urgent need to provide clear messages to patients with diabetes and their 
providers. Only a small proportion of patients with diabetes and CVD are 
currently treated with GLP-1 RA or SGLT2i {McCoy, 2019 #10057} and most 
astonishingly, prescription of these potentially life-saving medications by 
cardiologists remains very low (between 1 and 5%) {Vaduganathan, 2019 
#10059; Dave, 2020 #10058}. Both organisations agree on several compelling 
indications for with the use of GLP-1RA and SGLT2i which should be urgently 
implemented in clinical practice by cardiologists, endocrinologists, nephrologists, 
primary care providers, pharmacists and other licensed health care 
professionals. Subjects with T2DM and prevalent CVD or at high risk (prior MI, 
prior stroke, prior revascularization of any arterial bed, evidence of cardiac 
ischemia on any stress imaging procedure, a >50% arterial stenosis of presumed 
atherosclerotic origin, LVH) should be treated with a GLP-1RA or an SGLT2i.  
2) those with T2DM and heart failure, particularly those with reduced ejection 
fraction should be treated with an SGLT2i.  
3) Patients with T2DM with chronic kidney disease, particularly those with an 
estimated glomerular filtration rate (eGFR) 25-60 ml/min/1.73m2 or urine 
albumin/creatinine ratio (UACR) >200 mg/g, should be treated with an SGLT2i. If 
that is not tolerated or not preferred, a GLP-1RA should be considered.  
4) These treatment decisions should be made independent of background therapy, 
current levels of glycemic control or individualized treatment goals. The SGLT2i 
or GLP-1RA prescribed should have demonstrated outcome benefit in the 
relevant clinical setting.  
Of note, treatment with GLP-1RA and SGLT2i does not mean that the patient’s and 
provider’s work is done. Focusing on lifestyle management, achieving appropriate 
glycemic targets to minimize microvascular disease and decrements in quality of life, as 
well as the full panoply of cardiovascular risk reduction strategies remain foundational 
therapies implemented in all the trials in which the benefits of GLP-1RA and SGLT2i 
were demonstrated. In addition, there needs to be a more integrated approach to 
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patient care involving those from a diabetes, CV and CKD background in order to 
individualize overall care and harmonise the use of these agents. 
 
A call to action – clinical summary 
It is over 50 years since the publication of the UGDP trial, the first attempt to improve 
CV outcomes in diabetes {Goldner, 1971 #10012}. At the conclusion of this trial it was 
suggested that macrovascular outcomes were unlikely to be improved solely by 
glycaemic control. Later studies such as UKPDS largely supported this view with the 
caveat that good glycaemic control appeared to create metabolic memory and improved 
CV outcomes over 10 -15 years. These findings are in marked contrast to those 
reported in relation to the development of retinopathy, where glycaemic control is 
consistently shown to ameliorate risk of this condition. In summary, the glucocentric 
view of vascular complications works in relation to retinopathy but is insufficient on its 
own in preventing and managing macrovascular disease in diabetes.  
For many years diabetologists and other health care workers have lamented the 
seemingly unmanageable levels of macrovascular morbidity and mortality which 
became almost overwhelming with the concurrent development of renal disease. 
Moving forward again to 2020, we finally have in our armamentarium two groups of 
drugs that do what we have said we always wanted: they help to manage glycaemia 
and improve CV outcomes. The effects of SGLT2i on heart failure and renal impairment 
are particularly encouraging, no less the GLP-1RA on CV outcomes, weight loss and 
glycaemia. However at this historic moment in diabetes care, professionals from 
different medical specialties have been riven by uncertainty and disagreement about the 
precise positioning of these agents. We need to individually and collectively stop 
quibbling about where to draw distinctions, and ensure dissemination and 
implementation of points 1-4 above -- in your personal practice, among your colleagues 
and collaborators, in your health care system. It is a major worry that the very patients 
who will benefit from these agents, those at high risk with long standing diabetes, 
impaired renal function and underlying CV disease are being denied these evidence 
based agents through what is essentially, therapeutic inertia. All the myriad health care 
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professionals involved in diabetes care are asked to take note and to heed our call to 
action to prescribe newer glucose-lowering agents effectively and with confidence to 








Table 2. CVOTs with GLP1-RA in T2DM 
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Table 3. Differences between ADA / EASD recommendation and ESC guidelines 
 
 ADA / EASD ESC 
T2DM with established CVD For patients with T2DM 
and established 
atherosclerotic CV 
disease) where MACE is 
the gravest threat, the level 
of evidence for MACE 
benefit is greatest for GLP-





(ASCVD) should be 
treated with an SGLT2 
inhibitor or a GLP-1 RA  
 
T2DM without established CVD To reduce risk of MACE, 
GLP-1 receptor agonists 
can also be considered in 
patients with T2DM without 
established CVD with 
indicators of high risk, 
specifically, patients aged 
55 years or older with 
coronary, carotid, or lower 
extremity artery stenosis 
>50%, left ventricular 
hypertrophy, eGFR <60 mL 
min–1 [1.73 m]–2, or 
albuminuria. 
 
Patients) at high risk (DM 
duration ≥10 years without 
target organ damage plus 
any other additional risk 
factor; no ASCVD) should 
be treated with an SGLT2 
inhibitor or a GLP-1 RA  
Metformin use Metformin should be baseline 
therapy in all patients 
In patients at moderate 
risk metformin be should 
be considered as first line 
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